CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
inhibitor, in patients with relapsed or refractory acute myeloid leukemia (AML) as part of Phase 1. In Phase 2, assessment of ziftomenib wil...
Phase 1, Phase 2
Baltimore, Maryland, United States and 51 other locations
This study is a Phase 1, open-label, dose escalation, and cohort expansion study designed to characterize the safety, tolerability, pharmacokinetics,...
Phase 1
Baltimore, Maryland, United States and 8 other locations
allogeneic hematopoietic stem cell transplant (HCT), versus Conventional Care in patients with Active, Relapsed or Refractory Acute Myeloid Leukemia...
Phase 3
Washington, District of Columbia, United States and 23 other locations
Acute myeloid leukemia (AML) is the second most common type of leukemia diagnosed in adults and children, but most cases occur in a...
Phase 1
Baltimore, Maryland, United States and 23 other locations
chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will optimize the dose of study drug (rux...
Phase 2
Baltimore, Maryland, United States and 110 other locations
Eligible untreated patients with FLT3 acute myeloid leukemia (AML) between the ages of 18 and 70 will be randomized to receive gilteritinib ...
Phase 2
Baltimore, Maryland, United States and 43 other locations
The purpose of this study is to characterize the efficacy of ponatinib administered in 3 starting doses (45 mg, 30 mg, and 15 mg daily) in participan...
Phase 2
Baltimore, Maryland, United States and 85 other locations
People with acute myeloid leukemia (AML) are usually treated with chemotherapy. Some people with AML have a changed FLT3 gene which causes l...
Phase 1, Phase 2
Baltimore, Maryland, United States and 18 other locations
This study is to find out if treating Chronic Myelomonocytic Leukemia (CMML) with a study drug (ruxolitinib) can improve outcomes of patient...
Phase 2
Baltimore, Maryland, United States and 4 other locations
A study of acalabrutinib plus venetoclax (AV) versus venetoclax plus obinutuzumab (VO) in previously untreated chronic lymphocytic leukemia ...
Phase 3
Silver Spring, Maryland, United States and 40 other locations
Clinical trials
Research sites
Resources
Legal